Fortnite is now unavailable on iOS globally, Epic Games said Friday, after Apple blocked a bid to reinstate the popular game on the App Store in the U.S."Apple has blocked our Fortnite submission so we cannot release to the US App Store or to the Epic Games Store for iOS in the European Union," the official account or Fortnite wrote in a post on social media platform X. "Now, sadly, Fortnite on iOS will be offline worldwide until Apple unblocks it."CNBC has reached out to Apple for comment.Epic Games submit ...

Issuer Call Notice 15 May, 2025 To : BNP Paribas, as (the “Fiscal Agent, Principal Paying Agent and Listing Agent in Luxembourg’’);Paying Agent and Listing Agent in the Netherlands;The Noteholders of the below mentioned Notes;Luxembourg Stock Exchange; andEuronext Amsterdam. Dear Sirs, Banque Fédérative du Crédit Mutuel € 750,000,000 Undated Deeply Subordinated Fixed to Floating Rate Notes (the “Notes”) (ISIN Code: XS0207764712) Banque Fédérative du Crédit Mutuel is the issuer (the “Issuer’’) of ...

Core Points - GreenPower Motor Company Inc. has closed the first tranche of a secured term loan offering amounting to U.S. $500,000 [1] - The net proceeds from the loan will be allocated towards production costs, supplier payments, payroll, and working capital [2] - The loan is secured by a general security agreement on the company's assets and will bear an interest rate of 12% per annum for a term of two years [3] - The company issued 1,086,956 non-transferable share purchase warrants to the initial lenders, allowing them to purchase shares at an exercise price of U.S. $0.46 for 24 months [4] - The initial lenders are considered related parties, and the transaction is exempt from formal valuation and minority approval requirements [5] - All securities issued in connection with the loan will be subject to a statutory hold period of four months plus a day from the closing date [6] Company Overview - GreenPower designs, builds, and distributes a range of all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, and cargo vans [7] - The company employs a clean-sheet design approach to manufacture zero-emission vehicles, integrating global suppliers for key components [7] - GreenPower was founded in Vancouver, Canada, and has primary operational facilities in southern California, with a NASDAQ listing since August 2020 [7]

Financial Data and Key Metrics Changes - Sales for Q4 FY 2025 were $60 million, exceeding the estimated range of $15.5 million to $16.3 million [8][10] - Gross margin was reported at 29.3%, which was higher than expected given the circumstances [8][10] - Adjusted EBITDA for Q4 was within the estimated range of $3.3 million to $3.9 million [10] Business Line Data and Key Metrics Changes - C2B fabric sales accounted for $4.4 million in Q4, which was $500,000 more than predicted [18] - Total sales of C2B fabric for the entire fiscal year 2025 reached $7.5 million [19] - Production exceeded sales in Q4, allowing for a significant positive impact on EBITDA and inventory levels [16][17] Market Data and Key Metrics Changes - The company highlighted its position in niche military aerospace programs, including radomes and hypersonic materials, which are expected to drive future growth [32][76] - The A320neo family backlog remains strong with over 7,256 aircraft orders, although supply chain issues are affecting delivery rates [39] Company Strategy and Development Direction - The company is focusing on expanding its manufacturing capabilities to meet increasing demand, particularly in defense and missile programs [87][89] - A major new expansion of manufacturing facilities is planned, with an estimated capital budget of $35 million [86][94] - The company is also exploring joint ventures in Asia to enhance its manufacturing capabilities [67] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong demand in military defense markets and the successful ramp-up of production capabilities [76][87] - The company is committed to maintaining high standards of quality, aiming for a perfect score in supply chain performance [69] - Management acknowledged the challenges posed by supply chain issues but indicated that they have been able to mitigate tariff impacts effectively [72][74] Other Important Information - The company has entered into a new agreement to advance €4.58 million to Aireon for new manufacturing equipment, which will enhance C2B fabric production capacity [59] - The company has a strong history of cash dividends, having paid over $600 million in the last twenty years [83] Q&A Session Summary Question: Will the C2B fabric manufacturing equipment funded by Park be located at Aireon's facility or Park's facility? - The equipment will be located at Aireon's facility, and Aireon will own and operate it [78] Question: Does the Park MRAS LTA provide for any further price increases through 2029? - No, except for price increases related to increases in the cost of certain raw materials [79] Question: What is the status of the hypersonic missile program trials? - Trials are progressing well, with materials being built and tested, and updates expected in about six months [63][65]

Nexans Mixed Shareholders’ Meeting of May 15th, 2025 _PRESS RELEASE_ Paris La Défense, on May 15th, 2025 – Nexans Annual Shareholders' Meeting, held today in Paris, approved all 27 resolutions agreed by the Board of Directors. The voting results are available on the Nexans website. The Shareholders’ Meeting was broadcast live in French and English, and a replay will be available shortly on this same website.The shareholders adopted all the resolutions submitted, and thus approved: The distribution of a divi ...

Financial Data and Key Metrics Changes - In 2024, the company achieved a return on average tangible common equity of 18.8% and diluted earnings per share of $7.95, with annual net revenues reaching a record $61.8 billion and net income of $13.4 billion [5][6] - The first quarter of 2025 produced a 23% return on average tangible common equity, with a capital increase of $2 billion and a 10% growth in equity capital base over the last five quarters [9][10] Business Line Data and Key Metrics Changes - The Wealth Management and Investment Management businesses held $7.9 trillion in client assets at the end of 2024, on track to exceed $10 trillion [7] - The integrated firm strategy focuses on delivering strong results across wealth management, investment management, and institutional securities [6][8] Market Data and Key Metrics Changes - The company capitalized on an improved capital markets backdrop in 2024, leading to strong results and durable earnings [8] - The outlook for the markets is anticipated to be less predictable in the short term, with adjustments expected due to trade policy and fiscal changes [9][10] Company Strategy and Development Direction - The company aims to capitalize on long-term growth drivers across wealth and investment management and its global investment bank [11] - A focus on a well-defined strategy, experienced management team, and a culture of rigor and partnership is emphasized for long-term success [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a period of adjustment ahead, with higher volatility and uncertainty in the markets, but emphasizes the value of the company's global reach and insights [10][11] - The company is committed to prudent long-term planning despite near-term uncertainties [12] Other Important Information - The board of directors recommended against a shareholder proposal for disclosure of an energy supply ratio, which received only 13% support [27] - The company continues to invest in diversity and inclusion as a critical component of its culture and success [29][30] Q&A Session Summary Question: Inquiry on Diversity and Inclusion Programs - The company highlighted its commitment to investing in talent and creating an inclusive workplace, which is essential for serving clients and delivering strong returns [29][30]

Material sent to 3rd party lab for analysisMONTREAL, May 15, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today that further to its news release dated May 13, 2025, and ...

Material Produced in the Reactor and Collected in Product Recovery UnitMONTREAL, May 15, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company developing next-generation processes for advanced material manufacturing, would like to inform shareholders that HPQ Silica Polvere Inc. (“HSPI”) [1] proprietary Fumed Silica Reactor (FSR) Pilot Plant has reached a Significant Milestone during its 4th Phase-one batch test. HSPI’s technology suppl ...

"In addition to new orders, we began delivering our 208-inch extended wheelbase W56 step vans in April to a national customer through our partner, Revolv. We also secured a purchase order from a municipal fleet in Washington for two W4 CC trucks through one of our certified dealers, The Truck Shop. Expanding our product line remains a top engineering priority, and the development of the 140 kWh version of the W56 is progressing on schedule. We continue to receive strong feedback from potential customers at ...

Summary of Roivant Sciences (ROIV) Conference Call Company Overview - **Company**: Roivant Sciences (ROIV) - **Event**: BofA Annual Healthcare Conference - **Date**: May 14, 2025 Key Points Immunovant and Clinical Focus - Roivant is transitioning its focus to IVD 1402, a next-generation program, after late-stage studies in betoclimab for MG and CIDP [8] - Eric Vanker has taken over as CEO of Immunovant, emphasizing patient enrollment in Graves' disease as the top priority [9] - Graves' disease is identified as a unique opportunity with a large patient population and high unmet need [11] Market Dynamics and Patient Population - Approximately 350,000 Graves' patients in the US are refractory to current treatments, primarily methimazole [25] - The current treatment landscape for Graves' disease has not seen a novel drug in 70 years, creating a significant opportunity for Roivant [29] - The company aims to address the operational challenges of enrolling patients in clinical trials due to the lack of recent novel therapies [30] Value Proposition of Therapy - The therapy aims to improve patient quality of life by reducing reliance on methimazole and potentially achieving drug-free remission [36] - Evidence from phase two data shows that 76% of patients on high doses achieved T3 and T4 normalization, with 56% able to discontinue anti-thyroid drugs [46] - The company is also exploring the potential to reduce the onset of Thyroid Eye Disease (TED) in hyperthyroid patients with proptosis [38] Regulatory and Clinical Trial Insights - The FDA has shown enthusiasm for new therapies in Graves' disease, indicating a supportive regulatory environment [51] - The first GRAVE study will treat patients for six months before randomization to assess remission rates [41] - The company is optimistic about the potential for accelerated approval based on positive clinical outcomes [85] Myasthenia Gravis (MG) and CIDP Challenges - Roivant acknowledges the challenges of entering the MG market, dominated by Argenx, and recognizes the need for deeper clinical data to compete effectively [58] - The company aims to shift the focus in MG from treatment response to deeper remission endpoints, which could favor their drug's profile [61] Dermatomyositis and Other Programs - Roivant is preparing for a phase three trial in dermatomyositis, with expectations for regulatory approval based on statistical significance [78] - The company is also developing a pulmonary hypertension program, with data expected in the second half of next year [87] Legal Matters - Roivant is involved in litigation regarding intellectual property related to lipid nanoparticles used in COVID vaccines, with a jury trial scheduled for September 2025 [90] - Potential damages from the case could be substantial, given the scale of global COVID vaccine sales [93] Additional Insights - The company is focused on executing its current indications before exploring new opportunities, indicating a disciplined approach to R&D investment [66] - Roivant is evaluating its pipeline continuously and may announce new indications as they progress [66] This summary encapsulates the key discussions and insights from the Roivant Sciences conference call, highlighting the company's strategic focus, market opportunities, and ongoing challenges in the biopharmaceutical landscape.